BIO-key International (BKYI) 10-Q 14 Aug 17 2017 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 11, 2017
Document Information [Line Items]
Entity Registrant Name	BIO KEY INTERNATIONAL INC
Entity Central Index Key	1,019,034
Trading Symbol	bkyi
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		6,498,438
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
ASSETS
Cash and cash equivalents	$ 988,342	$ 1,061,307
Accounts receivable, net	847,889	1,563,246
Due from factor	29,462	53,638
Inventory	567,182	465,428
Software license rights	2,100,000	1,560,000
Prepaid expenses and other	203,113	206,677
Total current assets	4,735,988	4,910,296
Software license rights, net	9,253,008	10,598,411
Accounts receivable, net	1,070,000	1,570,000
Equipment and leasehold improvements, net	153,529	67,814
Deposits and other assets	8,712	8,712
Intangible assets, net	166,735	134,132
Total non-current assets	10,651,984	12,379,069
TOTAL ASSETS	15,387,972	17,289,365
LIABILITIES
Accounts payable	333,627	466,842
Accrued liabilities	421,350	335,323
Dividends payable	802,500	401,250
Deferred revenue	417,464	633,062
Total current liabilities	1,974,941	1,836,477
TOTAL LIABILITIES	1,974,941	1,836,477
Commitments and contingencies
STOCKHOLDERS’ EQUITY
Common stock: authorized, 170,000,000 shares; issued and outstanding; 6,493,290 and 6,093,843 of $.0001 par value at June 30, 2017 and December 31, 2016, respectively	649	609
Additional paid-in capital	79,359,032	78,253,413
Accumulated deficit	(65,946,670)	(62,801,154)
TOTAL STOCKHOLDERS’ EQUITY	13,413,031	15,452,888
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	15,387,972	17,289,365
Series A-1 Convertible Preferred Stock [Member]
STOCKHOLDERS’ EQUITY
Preferred stock	9	9
Series B-1 Convertible Preferred Stock [Member]
STOCKHOLDERS’ EQUITY
Preferred stock	$ 11	$ 11

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)	Jun. 30, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000
Common stock, par value (in dollars per share) | $ / shares	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	170,000,000	170,000,000
Common stock, shares issued (in shares)	6,493,290	6,093,843
Common stock, shares outstanding (in shares)	6,493,290	6,093,843
Reverse Stock Split [Member]
Common stock, reverse stock split, shares	12	12
Series A-1 Convertible Preferred Stock [Member]
Preferred stock, liquidation value | $	$ 100	$ 100
Preferred stock, shares issued (in shares)	90,000	90,000
Preferred stock, shares outstanding (in shares)	90,000	90,000
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	100,000	100,000
Series B-1 Convertible Preferred Stock [Member]
Preferred stock, liquidation value | $	$ 100	$ 100
Preferred stock, shares issued (in shares)	105,000	105,000
Preferred stock, shares outstanding (in shares)	105,000	105,000
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	105,000	105,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenues
Services	$ 134,061	$ 220,926	$ 454,648	$ 505,652
License fees and other	752,820	194,888	1,850,568	340,754
	886,881	415,814	2,305,216	846,406
Costs and other expenses
Cost of services	55,660	66,597	94,480	122,379
Cost of license fees and other	740,301	69,893	1,362,415	125,959
	795,961	136,490	1,456,895	248,338
Gross Profit	90,920	279,324	848,321	598,068
Operating Expenses
Selling, general and administrative	1,431,208	1,038,904	3,051,358	2,031,429
Research, development and engineering	449,049	566,448	942,493	1,055,849
Total Operating Expenses	1,880,257	1,605,352	3,993,851	3,087,278
Operating loss	(1,789,337)	(1,326,028)	(3,145,530)	(2,489,210)
Other income (expenses)
Interest income	8	7	14	13
Loss on derivative liabilities		(49,468)		(49,506)
Total other income (expenses)	8	(49,461)	14	(49,493)
Net loss	(1,789,329)	(1,375,489)	(3,145,516)	(2,538,703)
Convertible preferred stock dividends	(200,625)	(200,625)	(401,250)	(401,250)
Net loss available to common stockholders	$ (1,989,954)	$ (1,576,114)	$ (3,546,766)	$ (2,939,953)
Basic and Diluted Loss per Common Share (in dollars per share)	$ (0.32)	$ (0.29)	$ (0.57)	$ (0.53)
Weighted Average Shares Outstanding:
Basic and diluted (in shares)	6,359,974	5,523,072	6,228,197	5,516,726

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
CASH FLOW FROM OPERATING ACTIVITIES:
Net loss	$ (3,145,516)	$ (2,538,703)
Adjustments to reconcile net loss to cash used for operating activities:
Allowance for doubtful accounts	500,000
Depreciation	15,513	24,577
Amortization of intangible assets	6,833	6,803
Amortization of software license rights	729,755
Loss on derivative liabilities		49,506
Share-based and warrant compensation for employees and consultants	564,275	184,299
Stock based directors fees	10,008	39,999
Change in assets and liabilities:
Accounts receivable	715,357	1,092,661
Due from factor	24,176	35,098
Inventory	(101,754)	(131,394)
Software license rights	75,648
Prepaid expenses and other	16,556	4,348
Accounts payable	(133,215)	(462,136)
Accrued liabilities	86,027	(142,234)
Deferred revenue	(215,598)	(58,359)
Net cash used for operating activities	(851,935)	(1,895,535)
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures	(140,664)	(51,783)
Net cash used for investing activities	(140,664)	(51,783)
CASH FLOW FROM FINANCING ACTIVITIES:
Issuance of common stock	1,000,000
Preferred dividends paid		(334,476)
Costs to issue preferred and common stock	(80,366)	(32,619)
Net cash provided by financing activities	919,634	(367,095)
NET DECREASE IN CASH AND CASH EQUIVALENTS	(72,965)	(2,314,413)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	1,061,307	4,321,078
CASH AND CASH EQUIVALENTS, END OF PERIOD	988,342	2,006,665
Cash paid for:
Interest
Noncash Investing and financing activities
Accrual of dividends	401,250	200,625
Issuance of common stock for consultancy services	$ 114,585

Note 1 - Nature of Business and

Note 1 - Nature of Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Business Description and Accounting Policies [Text Block]	1. NATURE OF BUSINESS AND BASIS OF PRESENTATION Nature of Business BIO-key International, Inc. was founded in 1993 Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements include the accounts of BIO-key International, Inc. and its wholly-owned subsidiary (collectively, the “Company”, or “BIO-key”) and are stated in conformity with accounting principles generally accepted in the United States of America, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The operating results for interim periods are not may In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all necessary adjustments, consisting only of those of a recurring nature, and disclosures to present fairly the Company’s financial position and the results of its operations and cash flows for the periods presented. The balance sheet at December 31, 2016 not 10 December 31, 2016 ( 10 March 31, 2017. Recently Issued Accounting Pronouncements In May 2014, No. 2014 09, two one one December 15, 2016 not August 2015, 2015 14, 606 2015 14" 2014 09 one 2014 09 December 15, 2017 The Company is continuing to evaluate the standard’s impact on its consolidated results of operations and financial condition. BIO-key has conducted initial analyses, developed a project management plan relative to the process of adopting this ASU, and is currently completing detailed contract reviews to determine potential adjustments to existing accounting policies as well as to support an evaluation of the standard’s impact on the Company’s consolidated results of operations and financial condition. For the majority of BIO-key’s revenue arrangements, no January 1, 2018. In July 2015 No. 2015 11, 330 2015 11" 2015 11 2015 11 December 15, 2016, 2015 11 not In January 2016, 2016 01, 2016 01” 2016 01 December 15, 2017. 2016 01 In February 2016, 2016 02, 12 December 15, 2018, In August 2014, No. 2014 15, 2014 15, not one 2014 15 December 15, 2016, 2014 15 March 31, 2017. In March 2016, 2016 09, 2016 09” 2016 09 2016 09 December 15, 2016. not In July 2017, 2017 11, 260 480 815 480, not December 15, 2018, 2017 11, six June 30, 2017, not 9 Management does not not Reclassification Reclassifications occurred to certain prior year amounts in order to conform to the current year classifications. The reclassifications have no

Note 2 - Going Concern

Note 2 - Going Concern	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Going Concern [Text Block]	2. GOING CONCERN The Company has incurred significant losses to date, and at June 30, 2017, $66 June 30, 2017, $988,000, $1,061,000 December 31, 2016. The Company has financed itself in the past through access to the capital markets by issuing secured and convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. The Company estimates that it currently requires approximately $592,000 If the Company is unable to generate sufficient revenue to meet its goals, it will need to obtain additional third No not The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"), which contemplate continuation of the Company as a going concern, and assumes continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The matters described in the preceding paragraphs raise substantial doubt about the Company’s ability to continue as a going concern. Recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon the Company’s ability to meet its financing requirements on a continuing basis, and become profitable in its future operations. The accompanying consolidated financial statements do not

Note 3 - Accounts Receivable

Note 3 - Accounts Receivable	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	3. ACCOUNTS RECEIVABLE Accounts receivable are carried at original amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful receivables by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history, and current economic conditions. Accounts receivable are written off when deemed uncollectible. During the year ended December 31, 2016, may not $500,000 December 31, 2016 six June 30, 2017, $500,000. 48% June 30, 2017. June 30, December 31, 2017 2016 Accounts receivable - current $ 861,674 $ 1,577,031 Accounts receivable - non current 2,070,000 2,070,000 2,931,674 3,647,031 Allowance for doubtful accounts - current (13,785 ) (13,785 ) Allowance for doubtful accounts - non current (1,000,000 ) (500,000 ) Accounts receivable, net of allowance for doubtful accounts $ 1,917,889 $ 3,133,246

Note 4 - Share Based Compensati

Note 4 - Share Based Compensation	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	4. SHARE BASED COMPENSATION The following table presents share-based compensation expenses included in the Company’s unaudited condensed interim consolidated statements of operations: Three Months Ended June 30, 2017 2016 Selling, general and administrative $ 394,264 $ 44,303 Research, development and engineering 18,930 5,632 $ 413,194 $ 49,935 Six Months Ended June 30, 2017 2016 Selling, general and administrative $ 507,120 $ 190,181 Research, development and engineering 67,163 34,117 $ 574,283 $ 224,298

Note 5 - Factoring

Note 5 - Factoring	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Factoring [Text Block]	5. FACTORING Due from factor consisted of the following as of: June 30, December 31, 2017 2016 Original invoice value $ 117,850 $ 214,556 Factored amount (88,388 ) (160,918 ) Due from factor $ 29,462 $ 53,638 As of December 2011, 24 October 31, 2017. 35% 75% 2.75% 21% Three Months ended June 30, 2017 2016 Factoring fees $ 85,326 $ 108,351 Six Months ended June 30, 2017 2016 Factoring fees $ 133,717 $ 303,363

Note 6 - Inventory

Note 6 - Inventory	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Inventory Disclosure [Text Block]	6. INVENTORY Inventory is stated at the lower of cost, determined on a first first June 30, December 31, 2017 2016 Finished goods $ 341,264 $ 381,762 Fabricated assemblies 225,918 83,666 Total inventory $ 567,182 $ 465,428

Note 7 - Software Licenses and

Note 7 - Software Licenses and Rights	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Research, Development, and Computer Software Disclosure [Text Block]	7. SOFTWARE LICENSE RIGHTS On November 11, 2015, $12,000,000. 12 $2,100,000 The Company has determined the software license rights to be a finite lived intangible asset, and estimated that the software license rights shall be economically used over a 10 fourth 2015, not January 2017. first 2017. The remaining license rights are to be amortized over the greater of the following: 1 2 ten 3 three June 30, 2017 $1,405 $388,595. six June 30, 2017 $48,337 $729,755. $11,221,404 June 30, 2017. On December 31, 2015, third $180,000 three $22,020 $28,716 three six June 30, 2017, $48,396 $131,604 June 30, 2017. June 30, December 31, 2017 2016 Current software license rights $ 2,100,000 $ 1,560,000 Non-current software license rights 9,253,008 10,598,411 Total software license rights $ 11,353,008 $ 12,158,411

Note 8 - Earnings Per Share (EP

Note 8 - Earnings Per Share (EPS)	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Earnings Per Share [Text Block]	8. EARNINGS (LOSS) PER SHARE - COMMON STOCK (“EPS”) The Company’s basic EPS is calculated using net loss available to common shareholders and the weighted-average number of shares outstanding during the reporting period. Diluted EPS includes the effect from potential issuance of common stock, such as stock issuable pursuant to the exercise of stock options and warrants and the assumed conversion of convertible preferred stock. The reconciliation of the numerator of the basic and diluted EPS calculations was as follows for both of the following three six June 30, 2017 2016: Three Months ended June 30, Six Months ended June 30, 2017 2016 2017 2016 Basic Numerator: Net loss $ (1,789,329 ) $ (1,375,489 ) $ (3,145,516 ) $ (2,538,703 ) Convertible preferred stock dividends (200,625 ) (200,625 ) (401,250 ) (401,250 ) Net loss available to common stockholders $ (1,989,954 ) $ (1,576,114 ) $ (3,546,766 ) $ (2,939,953 ) Basic Denominator 6,359,974 5,523,072 6,228,197 5,516,726 Per Share Amount $ (0.32 ) $ (0.29 ) $ (0.57 ) $ (0.53 ) The following table summarizes the weighted average securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive due to the net losses for the three six June 30, 2017 2016: Three Months ended June 30, Six Months ended June 30, 2017 2016 2017 2016 Preferred stock 5,416,667 5,416,667 5,416,667 5,416,667 Stock options 35,706 13,040 44,580 3,495 Warrants 3,004 - 3,336 - Total 5,455,377 5,429,707 5,464,583 5,420,162 Items excluded from the diluted per share calculation because the exercise price was greater than the average market price of the common shares: Three Months ended June 30, Six Months ended June 30, 2017 2016 2017 2016 Stock options 218,761 215,000 218,761 229,583 Warrants 1,212,163 1,704,629 1,212,163 1,704,629 Total 1,430,924 1,919,629 1,430,924 1,934,212

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9. STOCKHOLDERS’ EQUITY Preferred Stock Within the limits and restrictions provided in the Company’s Certificate of Incorporation, the Board of Directors has the authority, without further action by the shareholders, to issue up to 5,000,000 $.0001 one June 30, 2017, 100,000 1 90,000 105,000 1 Series A- 1 On October 22 29, 2015, 84,500 1 $100.00 $8,450,000. November 11, 2015, 5,500 1 $100.00 $550,000. 1 1 $3.60 9.99% 1 6% April 1, July, 1, October 1, January 1 1 October 1, 2017, ten 10 January 1, 2018, The holders of the Series A- 1 one 1 not 1 1 $100.00 1 June 30, 2017, $540,000 1 October 1, 2016, January 1, 2017, April 1, 2017, July 1, 2017 December 31, 2016, $270,000 1 October 1, 2016 January 1, 2017 The Series A- 1 815 15, 815 40 15, $3.60 December 31, 2017, may ten 10 not Series B- 1 On November 11, 2015, 105,000 1 $100.00 $10,500,000. 1 1 $3.60 9.99% 1 2.5% April 1, July, 1, October 1, January 1 1 ten 10 The holders of the Series B- 1 one 1 not 1 1 $100.00 1 June 30, 2017, $262,500 1 October 1, 2016, January 1, 2017, April 1, 2017, July 1, 2017 December 31, 2016, $131,250 1 October 1, 2016 January 1, 2017 The Series B- 1 815 15, 815 40 15, $3.60 may ten 10 not Common Stock Effective December 29, 2016, 1 12. not December 29, 2016. On April 28, 2017, 277,778 $3.60 $1,000,000. On May 2, 2017, may $5.0 36 may $100,000 five $3.83 94% $3.83 19.99% May 2, 2017, 9.99% On March 15, 2017, 1,895 $5,003. March 8, 2016, 8,333 $16,000. On May 11, 2017, 1,925 $5,005. May 11, 2016, 41,174 $6,999. May 11, 2016, 100,000 $17,000. In May 2017, 55,000 $198,000. The Company immediately expensed the fee as it relates to the contingent use of the equity committed equity facility. In May 2017, 61,667 $2.54 $156,584. The Company deferred the cost to prepaid expense and is amortizing the expense over the length of the consultancy service agreement. Stock Issuance Costs Additional costs of $74,420 three June 30, 2017 six June 30, 2017, $80,366. Derivative Liabilities In connection with the issuances of equity instruments or debt, the Company may may may may 815, Securities Purchase Agreements dated October 25, 2013 November 8, 2013 Pursuant to a series of Private Investors Securities Purchase Agreements (the “PI SPA”), on October 25, 2013 November 8, 2013, 1,026,972 1,026,972 1,026,972 $3,697,100. $6.00 three 2016. In connection with the share issuances described above, and pursuant to a placement agency letter agreement, the Company paid the placement agent cash commissions equal to 8% 82,158 The cashless exercise features contained in the warrants were considered to be derivatives and the Company recorded warrant liabilities on the consolidated balance sheet. The Company initially recorded the warrant liabilities equal to their estimated fair value of $325,891. three June 30, 2016, $433. six June 30, 2016, $1,904. December 31, 2016, $0 fourth 2016. Securities Purchase Agreement dated November 13, 2014 Pursuant to a Securities Purchase Agreement, dated November 13, 2014, “November 2014 664,584 996,877 $1,595,000. The common stock has a purchase price reset feature. If at any time prior to the two January 29, 2015), $2.40 no Based on an evaluation as discussed in FASB ASC 815 15, 815 40 15, not The Company valued the purchase price reset feature using a Monte Carlo simulation at the date of issuance, and at quarterly reporting intervals until the expiration of the feature in January 2017, no 1 1 October November 2015, $3.60, November 2016 April 2017 $3.60. The warrants have a term of five $3.60 February 2015. $3.60 not As a result of the early adoption of ASU 2017 11 1 no no no Warrants On March 9, 2015, 47,917 one $2.52 March 8, 2020. six June 30, 2016, $11,625 On September 23, 2015, 69,445 $3.60 five The warrants have customary anti-dilution protections including a "full ratchet" anti-dilution adjustment provision which are triggered in the event the Company sells or grants any additional shares of common stock, options, warrants or other securities that are convertible into common stock at a price lower than $3.60 not As a result of the early adoption of ASU 2017 11 1 no no no The cashless exercise features contained in the warrants were initially considered to be derivatives and the Company recorded a warrant liability of $92,199 2015. June 30, 2016, $49,035. six June 30, 2016, $51,410. 2016, not 2016. Issuances of Stock Options On March 15, 2017, 40,000 four March 15, 2017, 4,167 three seven $2.64. On March 16, 2017, 1,120,000 three seven $2.65. On April 10, 2017, 10,000 three seven $2.64. The fair value of the options issued during the three June 30, 2017 April 10, 2017 $20,538 1.81%, 4.5, 0, 138%.

Note 10 - Segment Information

Note 10 - Segment Information	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	10. SEGMENT INFORMATION The Company has determined that its continuing operations are one 58% 78% three June 30, 2017 2016, 73% 80% six June 30, 2017 2016,

Note 11 - Fair Values of Financ

Note 11 - Fair Values of Financial Instruments	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Fair Value Disclosures [Text Block]	11. FAIR VALUES OF FINANCIAL INSTRUMENTS Cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, and due from factor, are carried at, or approximate, fair value because of their short-term nature.

Note 12 - Major Customers and A

Note 12 - Major Customers and Accounts Receivable	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	12. MAJOR CUSTOMERS AND ACCOUNTS RECEIVABLE For the three June 30, 2017 2016, three 52% three 48% six June 30, 2017 2016, three 44% three 48% Three customers accounted for 57% June 30, 2017. 100% June 30, 2017 December 31, 2016. $1,000,000 48% December 31, 2016, one 81%

Note 13 - Subsequent Events

Note 13 - Subsequent Events	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	13. SUBSEQUENT EVENTS On July 25, 2017, On August 9, 2017, 5,148

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements include the accounts of BIO-key International, Inc. and its wholly-owned subsidiary (collectively, the “Company”, or “BIO-key”) and are stated in conformity with accounting principles generally accepted in the United States of America, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The operating results for interim periods are not may In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all necessary adjustments, consisting only of those of a recurring nature, and disclosures to present fairly the Company’s financial position and the results of its operations and cash flows for the periods presented. The balance sheet at December 31, 2016 not 10 December 31, 2016 ( 10 March 31, 2017.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In May 2014, No. 2014 09, two one one December 15, 2016 not August 2015, 2015 14, 606 2015 14" 2014 09 one 2014 09 December 15, 2017 The Company is continuing to evaluate the standard’s impact on its consolidated results of operations and financial condition. BIO-key has conducted initial analyses, developed a project management plan relative to the process of adopting this ASU, and is currently completing detailed contract reviews to determine potential adjustments to existing accounting policies as well as to support an evaluation of the standard’s impact on the Company’s consolidated results of operations and financial condition. For the majority of BIO-key’s revenue arrangements, no January 1, 2018. In July 2015 No. 2015 11, 330 2015 11" 2015 11 2015 11 December 15, 2016, 2015 11 not In January 2016, 2016 01, 2016 01” 2016 01 December 15, 2017. 2016 01 In February 2016, 2016 02, 12 December 15, 2018, In August 2014, No. 2014 15, 2014 15, not one 2014 15 December 15, 2016, 2014 15 March 31, 2017. In March 2016, 2016 09, 2016 09” 2016 09 2016 09 December 15, 2016. not In July 2017, 2017 11, 260 480 815 480, not December 15, 2018, 2017 11, six June 30, 2017, not 9 Management does not not
Reclassification, Policy [Policy Text Block]	Reclassification Reclassifications occurred to certain prior year amounts in order to conform to the current year classifications. The reclassifications have no

Note 3 - Accounts Receivable (T

Note 3 - Accounts Receivable (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	June 30, December 31, 2017 2016 Accounts receivable - current $ 861,674 $ 1,577,031 Accounts receivable - non current 2,070,000 2,070,000 2,931,674 3,647,031 Allowance for doubtful accounts - current (13,785 ) (13,785 ) Allowance for doubtful accounts - non current (1,000,000 ) (500,000 ) Accounts receivable, net of allowance for doubtful accounts $ 1,917,889 $ 3,133,246

Note 4 - Share Based Compensa21

Note 4 - Share Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months Ended June 30, 2017 2016 Selling, general and administrative $ 394,264 $ 44,303 Research, development and engineering 18,930 5,632 $ 413,194 $ 49,935 Six Months Ended June 30, 2017 2016 Selling, general and administrative $ 507,120 $ 190,181 Research, development and engineering 67,163 34,117 $ 574,283 $ 224,298

Note 5 - Factoring (Tables)

Note 5 - Factoring (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	June 30, December 31, 2017 2016 Accounts receivable - current $ 861,674 $ 1,577,031 Accounts receivable - non current 2,070,000 2,070,000 2,931,674 3,647,031 Allowance for doubtful accounts - current (13,785 ) (13,785 ) Allowance for doubtful accounts - non current (1,000,000 ) (500,000 ) Accounts receivable, net of allowance for doubtful accounts $ 1,917,889 $ 3,133,246
Factoring Fees [Table Text Block]	Three Months ended June 30, 2017 2016 Factoring fees $ 85,326 $ 108,351 Six Months ended June 30, 2017 2016 Factoring fees $ 133,717 $ 303,363
Factored Accounts Receivable [Member]
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	June 30, December 31, 2017 2016 Original invoice value $ 117,850 $ 214,556 Factored amount (88,388 ) (160,918 ) Due from factor $ 29,462 $ 53,638

Note 6 - Inventory (Tables)

Note 6 - Inventory (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, December 31, 2017 2016 Finished goods $ 341,264 $ 381,762 Fabricated assemblies 225,918 83,666 Total inventory $ 567,182 $ 465,428

Note 7 - Software Licenses an24

Note 7 - Software Licenses and Rights (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Software License Rights [Table Text Block]	June 30, December 31, 2017 2016 Current software license rights $ 2,100,000 $ 1,560,000 Non-current software license rights 9,253,008 10,598,411 Total software license rights $ 11,353,008 $ 12,158,411

Note 8 - Earnings Per Share (25

Note 8 - Earnings Per Share (EPS) (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months ended June 30, Six Months ended June 30, 2017 2016 2017 2016 Basic Numerator: Net loss $ (1,789,329 ) $ (1,375,489 ) $ (3,145,516 ) $ (2,538,703 ) Convertible preferred stock dividends (200,625 ) (200,625 ) (401,250 ) (401,250 ) Net loss available to common stockholders $ (1,989,954 ) $ (1,576,114 ) $ (3,546,766 ) $ (2,939,953 ) Basic Denominator 6,359,974 5,523,072 6,228,197 5,516,726 Per Share Amount $ (0.32 ) $ (0.29 ) $ (0.57 ) $ (0.53 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months ended June 30, Six Months ended June 30, 2017 2016 2017 2016 Preferred stock 5,416,667 5,416,667 5,416,667 5,416,667 Stock options 35,706 13,040 44,580 3,495 Warrants 3,004 - 3,336 - Total 5,455,377 5,429,707 5,464,583 5,420,162 Three Months ended June 30, Six Months ended June 30, 2017 2016 2017 2016 Stock options 218,761 215,000 218,761 229,583 Warrants 1,212,163 1,704,629 1,212,163 1,704,629 Total 1,430,924 1,919,629 1,430,924 1,934,212

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2016	Dec. 31, 2015
Retained Earnings (Accumulated Deficit)	$ (65,946,670)	$ (62,801,154)
Cash and Cash Equivalents, at Carrying Value	988,342	$ 1,061,307	$ 2,006,665	$ 4,321,078
Expected Operational Costs Per Month	$ 592,000

Note 3 - Accounts Receivable (D

Note 3 - Accounts Receivable (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Allowance for Doubtful Accounts Receivable, Noncurrent	$ 1,000,000	$ 500,000
Percentage of Remaining Balance Owned Reserved	48.00%

Note 3 - Accounts Receivable -

Note 3 - Accounts Receivable - Summary of Accounts Receivable (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Accounts receivable - current	$ 861,674	$ 1,577,031
Accounts receivable - non current	2,070,000	2,070,000
	2,931,674	3,647,031
Allowance for doubtful accounts - current	(13,785)	(13,785)
Allowance for doubtful accounts - non current	(1,000,000)	(500,000)
Accounts receivable, net of allowance for doubtful accounts	$ 1,917,889	$ 3,133,246

Note 4 - Share Based Compensa29

Note 4 - Share Based Compensation - Expenses for Continuing Operations (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Share-based compensation expense	$ 413,194	$ 49,935	$ 574,283	$ 224,298
Selling, General and Administrative Expenses [Member]
Share-based compensation expense	394,264	44,303	507,120	190,181
Research and Development Expense [Member]
Share-based compensation expense	$ 18,930	$ 5,632	$ 67,163	$ 34,117

Note 5 - Factoring (Details Tex

Note 5 - Factoring (Details Textual)	1 Months Ended
	Dec. 31, 2011
Factoring Arrangement Term	2 years
Minimum [Member]
Factoring Fees Percent	2.75%
Maximum [Member]
Factoring Fees Percent	21.00%
Geographic Distribution, Foreign [Member]
Percentage Of Accounts Receivable Remitted By Factor	35.00%
Geographic Distribution, Domestic [Member]
Percentage Of Accounts Receivable Remitted By Factor	75.00%

Note 5 - Factoring - Due From F

Note 5 - Factoring - Due From Factor (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Original invoice value	$ 117,850	$ 214,556
Factored amount	(88,388)	(160,918)
Due from factor	$ 29,462	$ 53,638

Note 5 - Factoring - Fees (Deta

Note 5 - Factoring - Fees (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Factoring fees	$ 85,326	$ 108,351	$ 133,717	$ 303,363

Note 6 - Inventory - Components

Note 6 - Inventory - Components of Inventory (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Finished goods	$ 341,264	$ 381,762
Fabricated assemblies	225,918	83,666
Total inventory	$ 567,182	$ 465,428

Note 7 - Software Licenses an34

Note 7 - Software Licenses and Rights (Details Textual) - USD ($)	Dec. 31, 2015	Nov. 11, 2015	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Dec. 31, 2016
Software License Rights, Current			$ 2,100,000		$ 2,100,000		$ 2,100,000	$ 1,560,000
Amortization of Intangible Assets					6,833	$ 6,803
Software License Rights			11,353,008		11,353,008		11,353,008	12,158,411
Payments to Acquire Software	$ 180,000
License Costs			740,301	$ 69,893	1,362,415	$ 125,959
Software License Rights, Noncurrent			9,253,008		$ 9,253,008		9,253,008	$ 10,598,411
Licensing Agreements [Member]
Payments to Acquire Intangible Assets		$ 12,000,000
Finite-Lived Intangible Asset, Useful Life					10 years
Amortization of Intangible Assets			388,595		$ 729,755
Software License Rights			11,221,404		11,221,404		11,221,404
License Costs			1,405		48,337
Software License Rights [Member]
License Costs			22,020		28,716		48,396
Software License Rights, Noncurrent			$ 131,604		$ 131,604		$ 131,604

Note 7 - Software Licenses an35

Note 7 - Software Licenses and Rights - Summary of Software License Rights (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Software license rights	$ 2,100,000	$ 1,560,000
Software license rights, net	9,253,008	10,598,411
Total software license rights	$ 11,353,008	$ 12,158,411

Note 8 - Earnings Per Share (36

Note 8 - Earnings Per Share (EPS) - Reconciliation of Numerator of Basic and Diluted EPS Calculations (Details) - USD ($)	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Basic Numerator:
Net loss	$ (2,538,703)	$ (1,789,329)	$ (1,375,489)	$ (3,145,516)	$ (2,538,703)
Convertible preferred stock dividends	(401,250)	(200,625)	(200,625)	(401,250)	(401,250)
Net loss available to common stockholders	$ (2,939,953)	$ (1,989,954)	$ (1,576,114)	$ (3,546,766)	$ (2,939,953)
Basic Denominator (in shares)	5,516,726	6,359,974	5,523,072	6,228,197	5,516,726
Per Share Amount (in dollars per share)	$ (0.53)	$ (0.32)	$ (0.29)	$ (0.57)	$ (0.53)

Note 8 - Earnings Per Share (37

Note 8 - Earnings Per Share (EPS) - Securities Excluded From the Diluted Per Share Calculation (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Exercise Price Less Than Average Market Price Of Common Shares [Member]
Antidilutive securities (in shares)	5,455,377	5,429,707	5,464,583	5,420,162
Exercise Price Less Than Average Market Price Of Common Shares [Member] | Preferred Stock [Member]
Antidilutive securities (in shares)	5,416,667	5,416,667	5,416,667	5,416,667
Exercise Price Less Than Average Market Price Of Common Shares [Member] | Employee Stock Option [Member]
Antidilutive securities (in shares)	35,706	13,040	44,580	3,495
Exercise Price Less Than Average Market Price Of Common Shares [Member] | Warrant [Member]
Antidilutive securities (in shares)	3,004		3,336
Exercise Price Greater Than Average Market Price Of Common Shares [Member]
Antidilutive securities (in shares)	1,430,924	1,919,629	1,430,924	1,934,212
Exercise Price Greater Than Average Market Price Of Common Shares [Member] | Employee Stock Option [Member]
Antidilutive securities (in shares)	218,761	215,000	218,761	229,583
Exercise Price Greater Than Average Market Price Of Common Shares [Member] | Warrant [Member]
Antidilutive securities (in shares)	1,212,163	1,704,629	1,212,163	1,704,629

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Details Textual)	Jun. 30, 2017USD ($)$ / sharesshares	May 11, 2017USD ($)shares	May 02, 2017USD ($)$ / shares	Apr. 28, 2017USD ($)$ / sharesshares	Apr. 10, 2017$ / sharesshares	Mar. 16, 2017$ / sharesshares	Mar. 15, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 29, 2016	May 11, 2016USD ($)shares	Mar. 08, 2016USD ($)shares	Nov. 11, 2015USD ($)$ / sharesshares	Oct. 29, 2015USD ($)$ / sharesshares	Sep. 23, 2015USD ($)$ / sharesshares	Mar. 09, 2015$ / sharesshares	Nov. 13, 2014USD ($)$ / sharesshares	Nov. 08, 2013USD ($)shares	Oct. 25, 2013$ / sharesshares	May 31, 2017USD ($)$ / sharesshares	Jun. 30, 2017USD ($)$ / sharesshares	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)$ / sharesshares	Jun. 30, 2016USD ($)	Nov. 30, 2016$ / shares
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 0.0001																			$ 0.0001		$ 0.0001
Preferred Stock, Shares Authorized | shares	5,000,000																			5,000,000		5,000,000
Stock Issued During Period As a Commitment Fee, Shares | shares																			55,000
Stock Issued During Period As a Commitment Fee, Value | $																			$ 198,000
Proceeds from Issuance of Common Stock | $																						$ 1,000,000
Committed Equity Facility Amount | $			$ 5
Committed Equity Facility, Term			3 years
Maximum Dollar Amount of Shares to Purchase Based on Daily Volume Weighted Average Price of the Company’s Common Stock | $			$ 100,000
Period for Maximum Dollar Amount of Shares to Purchase			5 days
Percentage of Lowest VWAP That Equals or Exceeds Specified per Share Price under Committed Equity Facility			94.00%
Per Share Price That Is Used in Calculation for Purchase Price under Committed Equity Facility | $ / shares			$ 3.83
Equity Facility, Aggregate Sales Limitation, Percentage of Total Outstanding Share			19.99%
Maximum Ownership of Company’s Common Stock Requirement under Committed Equity Facility Sale, Percentage			9.99%
Stock Issued During Period, Shares, Issued for Services | shares																			61,667
Stock Issued During Period, Issued for Services, Weighted Average Share Price | $ / shares																			$ 2.54
Stock Issued During Period, Value, Issued for Services | $																			$ 156,584
Payments of Stock Issuance Costs | $																				$ 74,420		80,366	32,619
Dividends Payable | $	$ 401,250																			$ 401,250	$ 200,625	401,250	200,625
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares															$ 2.52
Class of Warrant or Right, Nonemployee Compensation Expense | $																							11,625
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares															47,917
Term Of Warrant															1 year
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value Amount | $																						$ 20,538
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																						1.81%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																						4 years 182 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																						0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate																						138.00%
September 2015 Warrants [Member]
Debt Instrument, Unamortized Discount | $														$ 92,199
Fair Value Adjustment of Warrants | $																					49,035		51,410
Promissory Note [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares														69,445
Warrants Issued Under PISPA [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings | $																					$ (433)		$ 1,904
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value | $								$ 0
Fair Value, Inputs, Level 3 [Member] | Warrants Issued Under PISPA [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances | $																	$ 325,891
Private Investor SPA [Member]
Stock Issued During Period, Value, New Issues | $																	$ 3,697,100
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																		$ 6
Term Of Warrant																	3 years
Placement Agent Warrants [Member]
Commissions and Fees, Percent of Gross Proceeds																	8.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares																	82,158
Private Investor SPA [Member]
Stock Issued During Period, Shares, New Issues | shares																664,584		1,026,972
Proceeds from Issuance of Private Placement | $																$ 1,595,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																$ 3.60								$ 3.60
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares																996,877
Term Of Warrant																5 years
Private Investor SPA [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues | shares																		1,026,972
Private Investor SPA [Member] | Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares																		1,026,972
Director and Executive Officer [member]
Proceeds from Issuance of Common Stock | $				$ 1,000,000
Stock Issued During Period, Shares, New Issues | shares				277,778
Share Price | $ / shares				$ 3.60
Director [Member]
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures | shares							1,895				8,333
Stock Granted, Value, Share-based Compensation, Net of Forfeitures | $							$ 5,003				$ 16,000
Stock Issued During Period, Shares, Issued for Services | shares		1,925								41,174
Stock Issued During Period, Value, Issued for Services | $		$ 5,005								$ 6,999
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares					$ 2.64
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | shares					10,000
Director [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					7 years
Chief Executive Officer [Member]
Stock Issued During Period, Shares, Issued for Services | shares										100,000
Stock Issued During Period, Value, Issued for Services | $										$ 17,000
Four Members of the Board of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | shares							40,000
Employee [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares							$ 2.64
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | shares							4,167
Employee [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period							3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period							7 years
Certain Officers, Employees, and Contractors [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares						$ 2.65
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | shares						1,120,000
Certain Officers, Employees, and Contractors [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period						7 years
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	12							12	12
Series A-1 Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 0.0001							$ 0.0001												$ 0.0001		$ 0.0001
Preferred Stock, Shares Authorized | shares	100,000							100,000												100,000		100,000
Preferred Stock, Shares Outstanding | shares	90,000							90,000												90,000		90,000
Preferred Stock, Dividend Rate, Percentage												6.00%
Period Preceding the Dividend Payment Date												10 days
Liquidation Value Per Share | $ / shares												$ 100
Dividends Payable | $	$ 540,000							$ 270,000												$ 540,000		$ 540,000
Stock Issued During Period, Shares, New Issues | shares												5,500	84,500
Share Price | $ / shares												$ 100	$ 100
Proceeds from Issuance of Convertible Preferred Stock | $												$ 550,000	$ 8,450,000
Initial Conversion Price | $ / shares												$ 3.60	$ 3.60
Series A-1 Convertible Preferred Stock [Member] | Maximum [Member]
Maximum Ownership as a Result of Conversion												9.99%
Series B-1 Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 0.0001							$ 0.0001												$ 0.0001		$ 0.0001
Preferred Stock, Shares Authorized | shares	105,000							105,000												105,000		105,000
Preferred Stock, Shares Outstanding | shares	105,000							105,000												105,000		105,000
Preferred Stock, Dividend Rate, Percentage												2.50%
Period Preceding the Dividend Payment Date												10 days
Liquidation Value Per Share | $ / shares												$ 100
Dividends Payable | $	$ 262,500							$ 131,250												$ 262,500		$ 262,500
Stock Issued During Period, Shares, New Issues | shares												105,000
Share Price | $ / shares												$ 100
Proceeds from Issuance of Convertible Preferred Stock | $												$ 10,500,000
Series B-1 Convertible Preferred Stock [Member] | Maximum [Member]
Maximum Ownership as a Result of Conversion												9.99%
September 2015 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares														$ 3.60
Term Of Warrant														5 years

Note 10 - Segment Information (

Note 10 - Segment Information (Details Textual)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Number of Reportable Segments			1
Geographic Concentration Risk [Member] | Sales Revenue, Net [Member] | North America [Member]
Concentration Risk, Percentage	58.00%	78.00%	73.00%	80.00%

Note 12 - Major Customers and40

Note 12 - Major Customers and Accounts Receivable (Details Textual)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017USD ($)	Jun. 30, 2016	Jun. 30, 2017USD ($)	Jun. 30, 2016	Dec. 31, 2016USD ($)
Percentage of Remaining Balance Owned Reserved			48.00%
Allowance for Doubtful Accounts Receivable, Noncurrent	$ 1,000,000		$ 1,000,000		$ 500,000
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Concentration Risk, Number of Major Customers	3	3	3	3
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Three Customers Member
Concentration Risk, Percentage	52.00%	48.00%	44.00%	48.00%
Customer Concentration Risk [Member] | Current Accounts Receivable [Member] | Three Customers Member
Concentration Risk, Percentage			57.00%
Customer Concentration Risk [Member] | Current Accounts Receivable [Member] | One Customer [Member]
Concentration Risk, Number of Major Customers					1
Concentration Risk, Percentage					81.00%
Customer Concentration Risk [Member] | Non-current Accounts Receivable [Member] | One Customer [Member]
Concentration Risk, Percentage			100.00%		100.00%

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - shares	Aug. 09, 2017	May 11, 2017	May 11, 2016	May 31, 2017
Stock Issued During Period, Shares, Issued for Services				61,667
Director [Member]
Stock Issued During Period, Shares, Issued for Services		1,925	41,174
Director [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, Issued for Services	5,148